Reality Check: The Real Threat to Semaglutide Isn't Just a Rival Drug — It's Pricing, and Novo Says So

The consensus threat to semaglutide is a better molecule — the next dual or triple agonist that out-loses-weight Wegovy. The fact that complicates that focus sits in Novo Nordisk's own disclosures: the franchise's biggest near-term pressure may be on price, and the company says so in its filings to the SEC.

Read the risk factors. Novo's 2025 annual report on Form 20-F (filed February 4, 2026) discloses that its Inflation Reduction Act price negotiations included semaglutide-based products — Ozempic, Rybelsus, and Wegovy. When a government program selects your three best-known drugs for negotiated pricing, that is not a rounding error; it is a structural change to the economics of the franchise, and it is on the record.

There is a second pricing lever in the more recent disclosures. Novo's fourth-quarter 2025 update (6-K, filed February 3, 2026) describes a most favoured nations agreement under which semaglutide medicines, including Wegovy and Ozempic, will see price changes aimed at offering them to more Americans at lower cost. Strip the spin and that is the company telling investors that U.S. prices on its flagship products are being reset downward by policy.

The demand side is not bulletproof either. An earlier second-quarter 2025 update pointed to lower growth expectations for Wegovy in the U.S. obesity market and for Ozempic in the U.S. GLP-1 diabetes market — the company itself trimming the growth story. Pile pricing pressure on top of moderating volume growth and you have a franchise facing the two-front squeeze that ends every blockbuster's hyper-growth phase.

Acknowledge the bull case: semaglutide remains one of the best-selling drug families in the world, and lower per-unit prices can be offset by higher volumes as access broadens. Novo is not in trouble; it is in transition. But the transition is exactly the point — the easy money phase, where price and volume both rise, is what the filings describe ending.

The EdgarBeast evidence index surfaces these disclosures across Novo's filings, letting a reader trace the pricing language from the annual 20-F into the quarterly updates. The lesson for anyone modeling the GLP-1 war: watch the next molecule, sure — but read the pricing risk the incumbent already wrote down.